Official press releases and media coverage

Our work is regularly covered by the leading media organisations around the world. This section serves as a repository of all official press releases issued by our Corporate Communications and Investor Relations teams. You can also browse through the selection of media articles on Laurus Labs and relevant reportage.


02 Aug 2019
Q1 FY20 Results: Revenues up by 2 percent


22 July 2019
Laurus Labs' exclusive distribution partner Rising Pharmaceuticals, launches Pregabalin Capsules in US market


12 July 2019
Laurus Labs completed the US FDA inspection of Unit 4 at Visakhapatnam


14 June 2019
USFDA inspection of API facilites Unit 1 & 3 at Visakhapatnam


02 May 2019
FY 19 : Laurus Labs revenues up by 11.5 percent in Q4


26 Mar 2019
FY 19 : Laurus Labs enters into strategic partnership agreement with the Global Fund


11 Mar 2019
FY 19 : Laurus Labs receives two approvals from USFDA


3 Feb 2019
FY 19 : Laurus Labs received tentative approval from USFDA under PEPFAR for TLD FDC


3 Feb 2019
FY 19 : USFDA Approval for TLD Tablets and EIR from USFDA


31 Jan 2019
FY 19 : Laurus Labs Revenue Grew 11% in Q3 FY19


1 Dec 2018
FY 18 : Laurus Labs and Aspen Pharmacare launch an improved triple combination HIV drug in South Africa


1 Nov 2018
FY 18 : Laurus Labs Financial Results Q2 FY2019 Press Release


23 Oct 2018
FY 18 : Press Release Laurus Labs Oct 23 2018


29 Aug 2018
FY 18 : Press Release 29 Aug 2018 - Metformin USFDA Approval


3 Aug 2018
FY 18 : Press Release of Q1 Results 2018-19


10 May 2018
FY 17 : Press Release of Q4 Results 2017-18


1 March 2018
FY 17 : Intimation of completion of USFDA inspection of unit2 with no observations


29 January 2018
FY 17 : Press Release of Q3 9M Results 2017-18


17 January 2018
FY 17 : LAURUS LABS CERTIFIED AS THE “GREAT PLACE TO WORK” IN THE LARGE SIZED ORGANISATIONCATEGORY IN INDIA


9 November 2017
FY 17 : Q2 H1 Results 2017-18 Press Release


10 November 2017
FY 17 : Analyst and Investor Meet Intimation 10-11-2017


15 September 2017
FY 17 : Unit 2 receives EIR from USFDA and completes German Regulatory Authority inspection;


18 August 2017
FY 17 : Laurus Labs completed the USFDA inspection of its API facilities Unit 1 & 3 at Visakhapatnam


10 August 2017
FY 17 : Press Release of Q1 Results 2017-18


5 July 2017
FY 17 : Laurus Labs Credit Rating Improved


18 May 2017
FY 17 : Laurus Labs PAT grows by 40%


9 February 2017
FY 17 : Laurus Labs demonstrates strong Q3 growth In the first quarterly results after successful IPO



27 March 2019
Laurus Labs joins hand with Global Fund to supply drugs


26 March 2019
Laurus Labs seals deal with Global Fund to supply ARV combination medicine


26 March 2019
Laurus Labs jumps 4% on strategic partnership with Global Fund


26 March 2019
Larus Labs enters agreement with Global Fund for supply of AIDS drugs


26 March 2019
Laurus Labs firms up after partnership with Global Fund


26 March 2019
Laurus Labs in pact with The Global Fund


26 March 2019
Laurus Labs enters into strategic partnership agreement with Global Fund


14 February 2019
Laurus Labs invests over $100 million on formulation biz


3 February 2019
Laurus Labs gets USFDA approval for HIV drug


3 February 2019
Laurus Labs gets USFDA nod for HIV drug


2 December 2018
Laurus Labs-Aspen Pharmacare launch HIV drug in South Africa


3 November 2018
Laurus Labs Vizag API unit gets 1 USFDA observation


2 November 2018
Laurus Labs Vizag API unit gets 1 USFDA observation


23 October 2018
Laurus Labs to expand its footprint in US, China


30 August 2018
Laurus Labs gets USFDA nod for diabetes drug


30 August 2018
Laurus Labs rises nearly 6% post USFDA approval for diabetes drug


29 August 2018
Laurus Labs gets USFDA nod for diabetes drug


29 August 2018
Laurus Labs gets USFDA nod for diabetes drug


11 August 2017
Expect to get 2 ANDA approvals in FY18: Laurus Labs


11 August 2017
LAURAS LABS Q1: PROFIT JUMPS 51%


22 May 2017
Laurus Labs Q4 net rises 39%


19 May 2017
Laurus Labs says API facility of Unit 2 completed successful USFDA inspection


19 May 2017
Laurus Labs Vizag unit clears USFDA inspection ahead of debut in US generics market


Laurus Labs standalone net profit rises 39.11% in the March 2017 quarter


31 March 2017
Laurus Labs' PAT increases by 39% to Rs 74.3-cr.


18 May 2017
Laurus Labs posts Rs 74 crore net profit in Q4


27 March 2017
Citi bullish on Laurus; return ratios will improve post formulations: Satyanarayana Chava, Founder & CEO


Laurus Labs December quarter net up 17.5% to Rs 47 crore


10 February 2017
Laurus Labs hopes better profits in Q4 with lower interest outgo after debt retirement


10 February 2017
Laurus Labs December quarter net up 17.5% to Rs 47 crore


10 February 2017
Laurus Labs Q3 net up 18%


Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO


9 February 2017
Laurus Labs net profit up 17.5% to Rs 47.2 crore in Q3


9 February 2017
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO


10 February 2017
Laurus Labs December quarter net up 17.5% to Rs 47 crore


Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO


11 February 2017
Laurus Labs December quarter net up 17.5% to Rs 47 crore


13 February 2017
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO


9 February 2017
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO


Laurus Labs Demonstrates Strong Q3 Growth In The First Quarterly Results After Successful IPO

Videos: